GCP
BOLT icon

GSA Capital Partners’s Bolt Biotherapeutics BOLT Stock Holding History

GSA Capital Partners’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,778
Closed -$53K – 1484
2022
Q3 		$53K Sell
1,778
-857
-33% -$35.5K 0.01% 1417
2022
Q2 		$107K Sell
2,635
-67
-2% -$2.6K 0.02% 1207
2022
Q1 		$148K Buy
+2,702
New +$182K 0.02% 1234

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

GSA Capital Partners's BOLT Position: Q4 2022 in Review

GSA Capital Partners sold out of Bolt Biotherapeutics (BOLT) in Q4 2022, closing a stake of 1,778 shares — an estimated $53K sold.

GSA Capital Partners first reported a position in BOLT in Q1 2022 and held it in 3 quarters. The position peaked at $148K in Q1 2022. 44 funds tracked by Wall St. Rank hold BOLT as of Q4 2022.

  • GSA Capital Partners reported no remaining Bolt Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • GSA Capital Partners sold 1,778 Bolt Biotherapeutics shares in Q4 2022, an estimated $53K.
  • GSA Capital Partners first reported a position in Bolt Biotherapeutics in Q1 2022 and held it in 3 quarters.
  • GSA Capital Partners's Bolt Biotherapeutics position peaked at $148K in Q1 2022.
  • 44 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.